@article{TAU1206,
author = {Matthias M. Heck and Jürgen E. Gschwend and Margitta Retz},
title = {Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients},
journal = {Translational Andrology and Urology},
volume = {2},
number = {2},
year = {2012},
keywords = {},
abstract = {Until lately, castration-resistant prostate cancer (CRPC) patients who progressed following docetaxel chemotherapy had no treatment alternative with proven survival benefit. This changed with a series of recently published phase III trials that lead to approval of several new, life-prolonging agents by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/1206}
}